{
  "id": 18028841,
  "title": "Earnings call transcript: Ardelyx tops growth goals in Q3 2026 as stock jumps",
  "url": "https://urgent.news/2026/11/03/earnings-call-transcript-ardelyx-tops-growth-goals-in-q3-2026-as",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-03T22:10:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-ardelyx-tops-growth-goals-in-q3-2026-as-stock-jumps-93CH-4996710"
  },
  "original_language": "en",
  "account": "In Ardelyx's third quarter earnings call for 2026, the biotech company reported a 19% increase in revenue compared to the previous year, reaching $125.5 million. While this was below the $129.22 million forecast, investors still responded positively, with the company's shares jumping 9.57% in after-hours trading to $3.32. The main growth driver was the product IBSRELA, which generated $96.3 million in revenue, a 23% increase year-over-year. XPHOZAH revenue grew 7% to $29.2 million. The net loss narrowed to $700,000 from $1 million a year earlier, indicating improved financial leverage. Shares rose in after-hours trading, suggesting investors focused on the strong demand for IBSRELA and Ardelyx's reaffirmed full-year guidance. Despite a modest revenue miss, Ardelyx's solid third quarter demonstrated both the growth and operating leverage of the business. The company held a strong cash position of $285.3 million, which will support continued investment in its pipeline as it works toward profitability in 2027. Ardelyx reaffirmed its full-year 2026 guidance, emphasizing the long-term growth potential of its products and the strength of its financial position.",
  "summary": null,
  "key_points": [
    "Ardelyx reported 19% revenue increase to $125.5 million in Q3 2026",
    "IBSRELA product drove 23% revenue growth to $96.3 million",
    "Shares jumped 9.57% in after-hours trading following guidance reaffirmation"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}